Market Performance
On October 24, Cipla’s share price slipped nearly 3%, even as the company revealed a major partnership with US-based pharma leader Eli Lilly. The fall comes just a day after Cipla touched its 52-week high of ₹1,673, extending its recent eight-session rally of over 7%.
By mid-day, Cipla shares were among the top losers on the Nifty 50 index, reflecting a phase of profit booking after a steady climb in the stock. Despite the short-term dip, the stock remains up over 19% from its 52-week low of ₹1,335, touched in April 2025.
In broader market terms, the decline in Cipla coincided with a mixed performance across the pharmaceutical pack, where investors seemed to lock in recent gains.
Main News: The Eli Lilly-Cipla Agreement
Cipla announced a significant collaboration with Eli Lilly to distribute and promote the drug Tirzepatide in India. The medicine, known globally for its dual role in managing Type 2 diabetes and chronic weight issues, will be marketed under a new brand name — ‘Yurpeak’.
Here’s what the agreement involves:
- Brand Name: Yurpeak
- Purpose: Used for treating Type 2 diabetes and chronic weight management
- Manufacturer: Eli Lilly
- Distributor & Promoter in India: Cipla
- Form: Multi-dose, single-patient use KwikPen
- Doses Available: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg
- Frequency: Once weekly administration
- Pricing: Same as Eli Lilly’s existing brand Mounjaro
The move positions Cipla as a key player in India’s fast-growing GLP-1 agonist market — a therapeutic category gaining massive traction globally due to rising diabetes and obesity cases.
Company Details
According to the companies’ joint statement issued on October 23, Eli Lilly will handle manufacturing and supply, while Cipla will focus on the distribution and promotion of Yurpeak across India.
The drug’s launch adds a second brand of Tirzepatide to the Indian market — after the success of Mounjaro — expanding accessibility for patients seeking advanced diabetes management options.
India currently has an estimated 101 million people living with diabetes, with nearly half of adult patients under inadequate treatment or suboptimal glycemic control, as highlighted in the ICMR-INDIAB national study. This underscores the scale of opportunity for advanced therapies like Tirzepatide.
Cipla Share Price Overview
The Cipla share price has been on an impressive run through 2025:
- Up over 4% year-to-date
- Gained 3% in the last six months
- Rallied 7% in eight sessions before the latest dip
- Hit a 52-week high of ₹1,673 on October 23, 2025
- Trading at a P/E ratio near 25
- Currently up 19% from its 52-week low of ₹1,335
The recent pullback appears more like profit-taking after a strong rally, rather than a reaction of concern to the Eli Lilly collaboration. The market had already priced in optimism around this partnership in the past few sessions.
Understanding the Market Sentiment
While Cipla’s tie-up with Eli Lilly signals strategic growth in the long term, short-term traders seem to be booking profits after a robust rally. The partnership strengthens Cipla’s portfolio in the chronic care segment, which continues to be one of the most lucrative spaces in Indian pharma.
This development also marks another global-to-Indian pharma partnership — reinforcing the growing trend of multinationals collaborating with domestic leaders to expand their reach in emerging markets.
Summary
- Cipla share price fell 3% on October 24 despite the major Eli Lilly partnership announcement.
- The deal brings Tirzepatide (Yurpeak) — a diabetes and obesity drug — to India under Cipla’s marketing wing.
- Cipla will distribute and promote Yurpeak, while Eli Lilly handles manufacturing.
- The drug will come in six fixed doses in KwikPen form, to be used once weekly.
- India’s diabetes population of over 100 million makes this market opportunity significant.
- Stock movement indicates profit booking, not a change in fundamentals.
Easy & quick
Leave A Comment?